Precigen (NASDAQ:PGEN) Stock Price Passes Below 200 Day Moving Average – Time to Sell?

Precigen, Inc. (NASDAQ:PGEN)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.01 and traded as low as $3.63. Precigen shares last traded at $3.81, with a volume of 7,885,584 shares.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PGEN shares. Zacks Research downgraded shares of Precigen from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Wall Street Zen downgraded Precigen from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, HC Wainwright raised their target price on Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a research report on Friday, November 14th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.50.

Precigen Stock Performance

The stock has a market cap of $1.34 billion, a P/E ratio of -2.73 and a beta of 1.07. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95. The company has a fifty day moving average of $4.44 and a 200 day moving average of $4.02.

Insider Activity at Precigen

In other news, Director Randal J. Kirk sold 1,900,036 shares of the company’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.18, for a total value of $7,942,150.48. Following the completion of the sale, the director owned 341,189 shares in the company, valued at $1,426,170.02. This represents a 84.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 47.10% of the company’s stock.

Institutional Investors Weigh In On Precigen

Institutional investors and hedge funds have recently modified their holdings of the stock. NBC Securities Inc. acquired a new position in shares of Precigen in the 4th quarter worth $38,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Precigen in the 3rd quarter valued at $39,000. Russell Investments Group Ltd. purchased a new position in Precigen in the 3rd quarter worth about $41,000. Mason Investment Advisory Services Inc. acquired a new stake in Precigen during the 4th quarter worth about $42,000. Finally, Abel Hall LLC purchased a new stake in Precigen during the fourth quarter valued at about $44,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.